Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Jun;47(6):2018-21.
doi: 10.1128/AAC.47.6.2018-2021.2003.

Influence of reduced susceptibility to glycopeptides on activities of vancomycin and teicoplanin against Staphylococcus aureus in experimental endocarditis

Affiliations

Influence of reduced susceptibility to glycopeptides on activities of vancomycin and teicoplanin against Staphylococcus aureus in experimental endocarditis

Juliette Pavie et al. Antimicrob Agents Chemother. 2003 Jun.

Abstract

The influence of reduced susceptibilities to glycopeptides on the activities of vancomycin and teicoplanin against an isogenic pair of clinical Staphylococcus aureus strains in experimental endocarditis was investigated. While vancomycin was similarly active against both strains, teicoplanin was approximately 100-fold less active against the resistant strain and selected for the emergence of more resistant subpopulations.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
In vitro population analysis of S. aureus Lim-1 and Lim-2 on vancomycin (A) and teicoplanin (B) agar. Population analyses were performed with overnight cultures (∼108 to 109 CFU/ml) that were serially diluted and plated onto BHI agar containing increasing concentrations of vancomycin (0 to 10 μg/ml) or teicoplanin (0 to 40 μg/ml) and incubated for 48 h at 37°C before enumeration of the CFU.
FIG. 2.
FIG. 2.
Time-kill curve studies with vancomycin (Vm) (A) and teicoplanin (Tc) (B) at various concentrations against S. aureus Lim-1 and Lim-2.
FIG. 3.
FIG. 3.
Ex vivo population analysis of S. aureus Lim-1 (A) and Lim-2 (B) on vancomycin agar. The two strains were from the vegetations of six different infected rabbits sampled at the start of therapy.

Similar articles

Cited by

References

    1. Aeschlimann, J. R., G. P. Allen, E. Hershberger, and M. J. Ryback. 2000. Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model. Antimicrob. Agents Chemother. 44:2991-2998. - PMC - PubMed
    1. Aeschlimann, J. R., E. Hershberger, and M. J. Ryback. 1999. Analysis of vancomycin population susceptibility profiles, killing activity, and postantibiotic effect against vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 43:1914-1918. - PMC - PubMed
    1. Backo, M., E. Gaenger, A. Burkart, Y. L. Chai, and A. S. Bayer. 1999. Treatment of experimental staphylococcal endocarditis due to a strain with reduced susceptibility to vancomycin: efficacy of ampicillin-sulbactam. Antimicrob. Agents Chemother. 43:2565-2568. - PMC - PubMed
    1. Boyle-Vavra, S., S. Berke, J. C. Lee, and R. S. Daum. 2000. Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates. Antimicrob. Agents Chemother. 44:272-277. - PMC - PubMed
    1. Centers for Disease Control and Prevention. 1997. Staphylococcus aureus with reduced susceptibility to vancomycin—United States, 1997. Morb. Mortal. Wkly. Rep. 46:765-766. - PubMed

MeSH terms